Priority Research Papers:
Expression of a germline variant in the N-terminal domain of the human DNA glycosylase NTHL1 induces cellular transformation without impairing enzymatic function or substrate specificity
Metrics: PDF 421 views | Full Text 557 views | ?
Carolyn G. Marsden1,4, Pawel Jaruga2, Erdem Coskun2,5, Robyn L. Maher1, David S. Pederson1, Miral Dizdaroglu2 and Joann B. Sweasy3
1 Department of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
2 Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
3 Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ 85724, USA
4 Present address: Saint Michael’s College, Colchester, VT 05439, USA
5 Present address: Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA
|Joann B. Sweasy,||email:||firstname.lastname@example.org|
Keywords: NTHL1; cellular transformation; germline variant; base excision repair
Received: January 05, 2020 Accepted: March 14, 2020 Published: June 16, 2020
Oxidatively-induced DNA damage, widely accepted as a key player in the onset of cancer, is predominantly repaired by base excision repair (BER). BER is initiated by DNA glycosylases, which locate and remove damaged bases from DNA. NTHL1 is a bifunctional DNA glycosylase in mammalian cells that predominantly removes oxidized pyrimidines. In this study, we investigated a germline variant in the N-terminal domain of NTHL1, R33K. Expression of NTHL1 R33K in human MCF10A cells resulted in increased proliferation and anchorage-independent growth compared to NTHL1 WT-expressing cells. However, wt-NTHL1 and R33K-NTHL1 exhibited similar substrate specificity, excision kinetics, and enzyme turnover in vitro and in vivo. The results of this study indicate an important function of R33 in BER that is disrupted by the R33K mutation. Furthermore, the cellular transformation induced by R33K-NTHL1 expression suggests that humans harboring this germline variant may be at increased risk for cancer incidence.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.